In this phase-III open-label trial, previously untreated patients with stage IV NSCLC and PD-L1 TPS > 50% were randomized to receive either pembrolizumab monotherapy or platinum-based chemotherapy as the first-line treatment. The gene discussed is CD274; the disease is non-small cell lung carcinoma.